Maintenance Therapy after Autologous Haematopoietic Stem Cell Transplantation (auto-HSCT) in Multiple Myeloma Patients with and without Minimal Residual Disease (MRD)
Maxim Solovev(National Medical Research Center for Hematology), Savchenko Vg(National Research Center for Hematology Russian Academy of Medical Sciences), Irina Galtseva(National Research Center for Preventive Medicine), Larisa A. Kuzmina(Ministry of Health of the Russian Federation), Julia Davydova(National Medical Research Center for Hematology), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), Olga S. Pokrovskaya, М. В. Фирсова(Ministry of Health of the Russian Federation), Э Г Гемджян(National Medical Research Center for Hematology)
Cited by 6
Related Papers
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Atlas of RNA sequencing profiles for normal human tissues
|Scientific Data|2019|142
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
|The Oncologist|2010|92
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
|Leukemia & lymphoma/Leukemia and lymphoma|2015|59